Gastrointestinal Pharmacotherapy

Therapy of pediatric functional gastrointestinal disorders is best done within the context of a multidisciplinary biopsychosocial approach. Pharmacotherapy is often sought by patients and families who hope to find a “pill” that will lead to rapid symptom relief. Yet, there is only scant published evidence for the efficacy of a variety of medical interventions in childhood functional abdominal pain and irritable bowel syndrome. This article reviews the pediatric studies that have addressed pharmacotherapy in children with pain predominant functional gastrointestinal disorders.

  • Hepato biliary Diseases
  • Therapy of Pancreatic Diseases
  • Inflamatory Bowl Diseases
  • Prokinetic Agents
  • Gastro Duodenal Mucosal Protection

Market Statistics:

Market analysts predict the global gastrointestinal medicines market will increase from $46.68 billion in 2020 to $48.74 billion in 2021, representing CAGR of 4.4% over the next five years. The market is estimated to reach $62.19 billion in 2025, growing at a CAGR of 6%.

North America dominated the worldwide gastrointestinal medicines market in 2020, accounting for 48% of the total. The second-largest region, Asia Pacific, accounted for 24% of the global gastrointestinal medicines market. 

Peptic ulcer Disease Conferences Endoscopic Conferences Inflamatory Bowl Disease Conference Hepatology Conferences 2023 Europe Thyroid Disease Conferences Gastroenterology 2023 Hepatology Conferences Pancreas Conferences 2023 Asia Colorectal Cancer Gastrointestinal Surgery Conferences Biliary Bowl Disease Conferences Hepatitis Conferences Gastroenterology Conferences 2023 Europe Gastroenterology Conferences 2023 Asia Gastrointestinal Disease Conferences